AAN 2025: CAR T-cell therapy shows safety, efficacy in 2 MS trials
Apr 15, 2025 · The CAR T-cell therapy KYV-101 is safe, and showed preliminary signs of efficacy in patients with progressive forms of MS in two trials.
AAN 2025: Frexalimab results promising over 2-year extension
Apr 14, 2025 · Frexalimab was well tolerated and maintained disease control over two years in adults with relapsing MS in an open-label extension trial.
AAN 2025: Gains from CNM-Au8 in RRMS tied to nerve cell repair
Apr 11, 2025 · Treatment with CNM-Au8 led to clinical improvements in relapsing-remitting MS patients that linked to signs of nerve cell repair, data show.
Tolebrutinib delays disability progression in nonrelapsing SPMS trial
Apr 11, 2025 · Tolebrutinib was found to delay disability progression in people with nonrelapsing secondary progressive MS in a Phase 3 clinical trial.
My plants may be dying, but I’m learning how to thrive
Apr 8, 2025 · Columnist Ahna Crum may not have a green thumb, but her plants have taught her valuable lessons about how to thrive in life with MS.
Foralumab shows promise in early study of nonactive SPMS
May 7, 2025 · Data from an open-label trial showed that foralumab treatment eased fatigue and lessened disability for some people with nonactive SPMS.
Certain spinal cord lesions may be markers of early MS damage
May 6, 2025 · Certain spinal cord lesions in people with MS show damage to nerve fibers despite having preserved myelin content, a possible early MS marker.
Broad rim lesions identified as MS disease progression marker
May 5, 2025 · Broad rim lesions, which have wider rims of immune cells, are associated with faster disease progression in MS, per a study.
National MS Society gives more than $18M for research, training
May 6, 2025 · More than $18 million in new research grants and fellowships were awarded toward MS research aligned with its Pathways to Cures initiative.
ACTRIMS 2025: Updated McDonald criteria could aid MS diagnosis
Mar 4, 2025 · Proposed McDonald criteria revisions could help diagnose MS patients who would have been missed with earlier versions, an analysis shows.